Stribild (HIV) - Forecast and Market Analysis to 2022

NEW YORK, April 11, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Stribild (HIV) - Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01158425/Stribild-HIV---Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Stribild (HIV) - Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, "Stribild (HIV) - Forecast and Market Analysis to 2022". Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.

Gilead's Stribild is a complete, fixed-dose regimen for antiretroviral-treatment-naïve adults with HIV. Stribild contains two NRTIs (emtricitabine/FTC and tenofovir disoproxil fumarate/TDF), a novel INI (elvitegravir/ELV) and a novel PK enhancer (cobicistat/COBI). Stribild's mechanism of action includes the following (Stribild prescribing information, 2012).

FTC, a synthetic nucleoside analog of cytidine, inhibits the activity of HIV reverse transcriptase (RT) by competing with a natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA resulting in the termination of replication.

TDF, an acyclic nucleoside phosphonate diester analog of adenosine monophosphate, is converted into its active form (i.e., tenofovir diphosphate) by normal metabolic processes. Tenofovir diphosphate inhibits the activity of the HIV RT by competing with deoxyadenosine 5'-triphosphate (a natural substrate), and terminating viral replication if the drug is incorporated into the viral DNA.

ELV inhibits the HIV integrase. This blocks HIV from integrating its DNA into host genomic DNA, which prevents HIV from replicating and propagating.

COBI enhances ELV bioavailability by selectively inhibiting cytochrome P450 enzymes of the CYP3A superfamily, which would otherwise decrease the bioavailability and half-life of ELV via metabolism. Cobicistat has no direct anti-HIV activity.

Scope

- Overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Stribild including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Stribild for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HIV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Stribild performance
- Obtain sales forecast for Stribild from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 13
3.1.3 Prognosis 13
3.1.4 Quality of Life 14
3.2 Symptoms 14
3.2.1 Primary or Acute Infection 14
3.2.2 Chronic Infection 14
3.2.3 Advanced Infection/AIDS 15
4 Disease Management 16
4.1 Treatment Overview 16
5 Competitive Assessment 20
5.1 Overview 20
5.2 Strategic Competitor Assessment 20
6 Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) 23
6.1 Efficacy 24
6.2 Safety 25
6.3 SWOT Analysis 25
6.4 Forecast 28
7 Appendix 29
7.1 Bibliography 29
7.2 Abbreviations 31
7.3 Methodology 33
7.4 Forecasting Methodology 33
7.4.1 HIV Prevalence 33
7.4.2 Percent Drug-Treated Patients 33
7.4.3 General Pricing Assumptions 34
7.4.4 Individual Drug Assumptions 35
7.4.5 Generic Erosion 35
7.5 Physicians and Specialists Included in this Study 36
7.5.1 Survery of Prescribing Physicians 37
7.6 About the Authors 37
7.6.1 Authors 37
7.6.2 Global Head of Healthcare 38
7.7 About GlobalData 39
7.8 Contact Us 39
7.9 Disclaimer 39

List of Tables

Table 1: Symptoms HIV 15
Table 2: Treatment Guidelines for HIV 17
Table 3: Most Prescribed Drugs for HIV by Class in the Global Markets, 2012 18
Table 4: Leading Treatments for HIV, 2012 22
Table 5: Product Profile – Stribild 24
Table 6: Stribild SWOT Analysis, 2012 27
Table 7: Global Sales Forecasts ($m) for Stribild, 2012-2022 28
Table 8: Physicians Surveyed, By Country 37

List of Figures

Figure 1: HIV Lifecycle 11

To order this report:
Pathology Industry: Stribild (HIV) - Forecast and Market Analysis to 2022


Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker